Maggie L. Shaw

Organized screening in Hong Kong narrowed socioeconomic disparities over 9 years, although suboptimal uptake persists in key groups.

Phlebotomy is used in polycythemia vera to reduce hematocrit levels below 45%, and is the most common treatment for the myeloproliferative neoplasm.

As GLP-1 approvals expand into new indications, claims data reveal most treated patients already qualify under multiple indications.

At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.

Bridget Vazquez, PsyD, breaks down how cancer-related PTSD manifests, why it goes unrecognized, and what patients, caregivers, and clinicians can do.

The dual glucagon/GLP-1 receptor agonist is also being studied in the SYNCHRONIZE-2, SYNCHRONIZE-CVOT, LIVERAGE, and LIVERAGE-Cirrhosis trials.

Kerry Rogers, MD, examines the underemphasized BTK inhibitor adverse effects that quietly erode patient quality of life—and what to do about them.

Four experts examine what updated dietary and obesity guidelines mean for diabetes care, and why personalized, equitable nutrition is now essential.

Diet quality, carbohydrate quantity, and macronutrient composition may influence gestational glycemia, with consequences well into the postpartum period.

Two new studies reveal how social determinants shape cognitive risk in prediabetes and type 2 diabetes, complicating the path to prevention.

AI tools for carbohydrate estimation and clinical decision support are reshaping how diabetes is managed, but human oversight remains essential.

CLL’s intrinsic immune dysfunction spans humoral, cellular, and innate defects, persisting even with targeted therapy.

Ajai Chari, MD, unpacks resistance mechanisms, treatment sequencing, and why myeloma’s future may be brighter than anyone predicted.

Alexa Simon Meara, MD, MS, discusses breaking down silos between academic and community oncology to improve immunotherapy care and irAE management.

GLP-1s, care standards updates, nutritional guidance, and AI adoption in diabetes management are just a few of the hot topics to be presented and debated.

Amid the genomic revolution reshaping AML treatment, Karilyn Larkin, MD, speaks to why every patient deserves a personalized road to cure.

Trauma after cancer is underdiagnosed and often persists into survivorship, with experts urging trauma-informed screening in oncology care.

Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens.

Data over 17 years from a new analysis contrast prior research in this area, but remain promising on the use of intravenous immunoglobulin in this hematologic cancer.

Emily Curran, MD, explains how newer immunotherapies are reshaping B-cell ALL treatment for older adults and why 10-year-old assumptions no longer apply.

Kerry Rogers, MD, breaks down the clinical and lifestyle factors that drive frontline treatment selection between BTK inhibitors and venetoclax regimens.

This new analysis highlights zanubrutinib’s survival benefits and lower cardiac toxicity in chronic lymphocytic leukemia.

Pharmacists need better support to manage emotional strain tied to patient suffering, treatment costs, and care decisions, says Karen Fancher, PharmD, BCOP.

New review details biologic, psychosocial, and treatment barriers shaping outcomes in AYA acute lymphoblastic leukemia (ALL).

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know about managing infections and CRS.

Adam Kittai, MD, weighs the favorable safety profile of acalabrutinib plus venetoclax against lingering unknowns on long-term efficacy and high-risk patients.

Diana Verrilli, MS, of Navista breaks down the regulatory, payer, and cybersecurity pressures threatening community oncology practices—and maps a path forward.

Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML.

Researchers found major differences between smoldering myeloma risk tools, raising concerns about overtreatment and defining “high risk.”

Efficacy and safety top the list for patients and physicians making R/R CLL treatment decisions, yet fewer than 1 in 3 patients felt their doctor fully answered their questions.